Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM AMINOSALICYLATE vs INH
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
Adjunctive treatment of tuberculosis (as second-line agent),Off-label: treatment of ulcerative colitis (as mesalamine prodrug)
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
0.5-1.5 hours for parent drug; acetylated metabolite half-life 2-3 hours; accumulation occurs in renal impairment.
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Hepatic (acetylation to N-acetyl-4-aminosalicylic acid and other metabolites); also undergoes intestinal metabolism by gut bacteria.
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Renal: >80% as metabolites (acetyl, glycolyl conjugates) and unchanged drug; fecal: <5%.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
50-60% bound to albumin.
0-10% (low binding; primarily albumin).
0.2-0.4 L/kg; reflects distribution into total body water with limited tissue penetration.
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Oral: ~90% absorbed; food may delay absorption.
Oral: ~90%. Intramuscular: ~100%.
GFR <50 m L/min: not recommended due to risk of accumulation; if unavoidable, reduce dose to 4 g once daily. GFR <30 m L/min: avoid use.
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% (to 2 g twice daily). Child-Pugh Class C: avoid use.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Children: 200-300 mg aminosalicylic acid base per kg body weight per day, divided into 2 doses. Maximum 8 g/day.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
Start at lower end of dosing (4 g once daily) due to potential decreased renal function and increased risk of gastrointestinal intolerance.
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
No FDA black box warning.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
Hypersensitivity reactions including fever and rash,Hepatotoxicity (discontinue if jaundice or liver enzyme elevation occurs),Renal impairment may require dose adjustment,Gastrointestinal intolerance,May cause hypocalcemia and hypokalemia,Interference with thyroid function tests
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Hypersensitivity to any salicylate component,Severe hepatic disease,Severe renal impairment (e GFR < 30 m L/min)
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid large amounts of high-potassium foods (e.g., bananas, oranges, potatoes) unless directed by a physician, as this drug may alter potassium levels. No specific food restrictions beyond these.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
Excreted in breast milk; M/P ratio unknown. Caution due to potential for infant methemoglobinemia or gastrointestinal disturbances.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
No specific dose adjustment recommended; standard doses may be used, but monitor for potassium disturbances due to pregnancy-induced hypervolemia.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Monitor for hepatotoxicity, including elevated liver enzymes and bilirubin, especially in the first 3 months of therapy. Administer with food to reduce GI upset. Concurrent use with rifampin may decrease rifampin levels; separate doses by 8-12 hours. Contraindicated in severe renal impairment (Cr Cl < 30 m L/min) due to risk of hypokalemia and salicylate toxicity. Hypersensitivity reactions including fever, rash, and eosinophilia may occur; discontinue if severe.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
Take this medication with food or milk to prevent stomach upset.,Do not take antacids containing aluminum or magnesium within 3 hours of this medication.,Avoid alcohol while taking this medication due to increased risk of liver damage.,Report any signs of liver problems (yellowing skin or eyes, dark urine, abdominal pain) to your doctor immediately.,Use effective contraception during treatment as this drug may harm an unborn baby.,Do not stop taking this medication without consulting your doctor, even if you feel better.,Keep all appointments for blood tests to monitor liver function and potassium levels.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM AMINOSALICYLATE vs INH, answered by our medical review team.
POTASSIUM AMINOSALICYLATE is a Antitubercular Agent that works by Exact mechanism unknown; may competitively inhibit folic acid synthesis and/or disrupt mycobacterial cell wall metabolism via inhibition of salicylate hydroxylation.. INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM AMINOSALICYLATE and INH depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM AMINOSALICYLATE is: Adults: 4 g (as granules or powder) orally twice daily, equivalent to 8 g/day of aminosalicylic acid base.. The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM AMINOSALICYLATE and INH in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM AMINOSALICYLATE is classified as Category C. First trimester: Insufficient data; no known human teratogenicity but animal studies inconclusive. Second/third trimester: No documented fetal harm; use only if clearly needed.. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.